Karuna Therapeutics Key Executives
This section highlights Karuna Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Karuna Therapeutics
(Showing 0 of )
Karuna Therapeutics Earnings
This section highlights Karuna Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q3 | 2023 | 2023-11-05 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-05 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-05-06 | N/A | N/A |
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
$329.83
Stock Price
$12.60B
Market Cap
339
Employees
Boston, MA
Location
Financial Statements
Access annual & quarterly financial statements for Karuna Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $654.00K | $10.64M | $36.96M | $- | $- |
| Cost of Revenue | $1.70M | $1.11M | $506.00K | $145.00K | $58.00K |
| Gross Profit | $-1.05M | $9.53M | $36.46M | $-145.00K | $-58.00K |
| Gross Profit Ratio | -160.10% | 89.55% | 98.60% | 0.00% | 0.00% |
| Research and Development Expenses | $364.10M | $224.25M | $128.20M | $43.41M | $24.54M |
| General and Administrative Expenses | $131.33M | $76.07M | $52.62M | $28.41M | $20.87M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $131.33M | $76.07M | $52.62M | $28.41M | $20.87M |
| Other Expenses | $588.00K | $580.00K | $254.00K | $- | $- |
| Operating Expenses | $495.43M | $300.31M | $180.82M | $71.82M | $45.41M |
| Cost and Expenses | $495.43M | $300.31M | $180.82M | $71.82M | $45.41M |
| Interest Income | $61.18M | $14.18M | $502.00K | $3.31M | $2.53M |
| Interest Expense | $- | $14.18M | $- | $- | $945.00K |
| Depreciation and Amortization | $1.70M | $1.11M | $702.00K | $3.31M | $2.53M |
| EBITDA | $-493.08M | $-289.68M | $-143.15M | $-68.51M | $-42.88M |
| EBITDA Ratio | -75393.88% | -2723.29% | -387.27% | 0.00% | 0.00% |
| Operating Income | $-494.78M | $-289.68M | $-143.85M | $-71.82M | $-45.41M |
| Operating Income Ratio | -75653.98% | -2723.29% | -389.17% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $61.77M | $14.76M | $54.00K | $3.31M | $1.45M |
| Income Before Tax | $-433.01M | $-274.92M | $-143.80M | $-68.51M | $-43.96M |
| Income Before Tax Ratio | -66209.48% | -2584.54% | -389.02% | 0.00% | 0.00% |
| Income Tax Expense | $670.00K | $1.42M | $6.00K | $43.00K | $887.00K |
| Net Income | $-433.68M | $-276.34M | $-143.81M | $-68.55M | $-44.84M |
| Net Income Ratio | -66311.93% | -2597.88% | -389.04% | 0.00% | 0.00% |
| EPS | $-11.73 | $-8.74 | $-4.94 | $-2.59 | $-3.75 |
| EPS Diluted | $-11.73 | $-8.74 | $-4.94 | $-2.59 | $-3.75 |
| Weighted Average Shares Outstanding | 36.96M | 31.63M | 29.14M | 26.45M | 11.96M |
| Weighted Average Shares Outstanding Diluted | 36.96M | 31.63M | 29.14M | 26.45M | 11.96M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $654.00K | $5.28M | $81.00K | $5.28M | $- | $36.96M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $447.00K | $458.00K | $469.00K | $327.00K | $305.00K | $290.00K | $269.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $-447.00K | $-458.00K | $-469.00K | $327.00K | $4.97M | $-209.00K | $5.01M | $- | $36.96M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 50.00% | 94.20% | -258.00% | 94.90% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $82.19M | $103.95M | $92.49M | $85.47M | $66.00M | $61.95M | $52.49M | $43.81M | $45.09M | $38.77M | $24.15M | $20.19M | $15.58M | $12.59M | $10.82M | $4.42M | $4.99M | $5.79M | $6.78M | $6.97M |
| General and Administrative Expenses | $47.39M | $32.27M | $27.42M | $24.25M | $24.31M | $19.12M | $17.84M | $14.79M | $20.06M | $12.39M | $10.38M | $9.78M | $8.82M | $6.94M | $7.01M | $5.63M | $3.87M | $4.10M | $8.29M | $4.61M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $47.39M | $32.27M | $27.42M | $24.25M | $24.31M | $19.12M | $17.84M | $14.79M | $20.06M | $12.39M | $10.38M | $9.78M | $8.82M | $6.94M | $7.01M | $5.63M | $3.87M | $4.10M | $8.29M | $4.61M |
| Other Expenses | $147.00K | $147.00K | $147.00K | $147.00K | $147.00K | $147.00K | $147.00K | $139.00K | $123.00K | $122.00K | $9.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $129.59M | $136.22M | $119.91M | $109.72M | $90.31M | $81.08M | $70.33M | $58.59M | $65.16M | $51.17M | $34.53M | $29.96M | $24.41M | $19.53M | $17.82M | $10.05M | $8.87M | $9.90M | $15.07M | $11.57M |
| Cost and Expenses | $129.59M | $136.22M | $119.91M | $109.72M | $90.31M | $81.08M | $70.33M | $58.59M | $65.16M | $51.17M | $34.53M | $29.96M | $24.41M | $19.53M | $17.82M | $10.05M | $8.87M | $9.90M | $15.07M | $11.57M |
| Interest Income | $16.29M | $16.95M | $16.60M | $11.35M | $9.57M | $3.88M | $490.00K | $237.00K | $139.00K | $114.00K | $106.00K | $143.00K | $441.00K | $688.00K | $779.00K | $1.40M | $1.09M | $858.00K | $452.00K | $115.00K |
| Interest Expense | $11.49M | $- | $- | $- | $9.57M | $3.88M | $490.00K | $237.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $522.00K | $412.00K |
| Depreciation and Amortization | $447.00K | $458.00K | $469.00K | $327.00K | $305.00K | $290.00K | $269.00K | $248.00K | $236.00K | $106.00K | $52.00K | $112.00K | $48.00K | $43.00K | $33.00K | $21.00K | $21.00K | $15.00K | $12.00K | $10.00K |
| EBITDA | $-129.14M | $-136.22M | $-119.91M | $-109.07M | $-85.04M | $-80.70M | $-64.78M | $-58.35M | $-28.17M | $-51.06M | $-34.48M | $-29.17M | $-23.97M | $-18.80M | $-17.01M | $-8.64M | $-7.77M | $-9.02M | $-14.61M | $-11.45M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -16676.76% | -1611.14% | -99634.57% | -1227.42% | 0.00% | -76.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-129.59M | $-136.22M | $-119.91M | $-109.07M | $-85.04M | $-80.99M | $-65.05M | $-58.59M | $-28.19M | $-51.17M | $-34.53M | $-29.96M | $-24.41M | $-19.53M | $-17.82M | $-10.05M | $-8.87M | $-9.90M | $-15.07M | $-11.57M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -16676.76% | -1611.14% | -99992.59% | -1232.51% | 0.00% | -76.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $16.43M | $17.10M | $16.74M | $11.49M | $9.71M | $4.03M | $637.00K | $376.00K | $237.00K | $236.00K | $115.00K | $-534.00K | $441.00K | $688.00K | $779.00K | $1.40M | $1.09M | $858.00K | $-70.00K | $-432.00K |
| Income Before Tax | $-113.15M | $-119.12M | $-103.16M | $-97.57M | $-75.32M | $-76.96M | $-64.42M | $-58.22M | $-27.95M | $-50.93M | $-34.42M | $-30.50M | $-23.97M | $-18.84M | $-17.05M | $-8.66M | $-7.77M | $-9.04M | $-15.14M | $-12.01M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -14919.57% | -1427.09% | -95016.05% | -1220.44% | 0.00% | -75.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $670.00K | $-17.41M | $-17.07M | $-11.49M | $890.00K | $-7.92M | $528.00K | $-613.00K | $6.00K | $-114.00K | $-106.00K | $534.00K | $43.00K | $688.00K | $779.00K | $1.40M | $1.07M | $858.00K | $452.00K | $412.00K |
| Net Income | $-113.82M | $-119.12M | $-103.16M | $-86.08M | $-76.21M | $-69.05M | $-64.94M | $-57.60M | $-27.96M | $-50.93M | $-34.42M | $-30.50M | $-24.01M | $-18.84M | $-17.05M | $-8.66M | $-7.77M | $-9.04M | $-15.14M | $-12.01M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -13162.39% | -1443.96% | -85244.44% | -1230.45% | 0.00% | -75.64% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-3.01 | $-3.16 | $-2.75 | $-2.47 | $-2.22 | $-2.13 | $-2.17 | $-1.93 | $-0.94 | $-1.72 | $-1.17 | $-1.10 | $-0.89 | $-0.71 | $-0.65 | $-0.33 | $-0.32 | $-0.39 | $-146.02 | $-0.56 |
| EPS Diluted | $-3.01 | $-3.16 | $-2.75 | $-2.47 | $-2.22 | $-2.13 | $-2.17 | $-1.93 | $-0.94 | $-1.72 | $-1.17 | $-1.10 | $-0.89 | $-0.71 | $-0.65 | $-0.33 | $-0.32 | $-0.39 | $-146.02 | $-0.56 |
| Weighted Average Shares Outstanding | 37.78M | 37.69M | 37.52M | 34.80M | 34.41M | 32.35M | 29.90M | 29.81M | 29.69M | 29.57M | 29.48M | 27.79M | 26.88M | 26.66M | 26.19M | 26.04M | 24.43M | 22.91M | 103.68K | 21.37M |
| Weighted Average Shares Outstanding Diluted | 37.78M | 37.69M | 37.52M | 34.80M | 34.41M | 32.35M | 29.90M | 29.81M | 29.69M | 29.57M | 29.48M | 27.79M | 26.88M | 26.66M | 26.19M | 26.04M | 24.43M | 22.91M | 103.68K | 21.37M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $185.82M | $248.33M | $206.95M | $53.05M | $208.93M |
| Short Term Investments | $1.08B | $875.72M | $287.04M | $269.28M | $180.47M |
| Cash and Short Term Investments | $1.26B | $1.12B | $493.99M | $322.33M | $389.40M |
| Net Receivables | $4.90M | $57.00K | $1.75M | $- | $- |
| Inventory | $32.83M | $28.32M | $20.89M | $- | $- |
| Other Current Assets | $14.77M | $2.34M | $708.00K | $1.09M | $485.00K |
| Total Current Assets | $1.32B | $1.15B | $517.33M | $344.60M | $392.71M |
| Property Plant Equipment Net | $20.51M | $7.88M | $9.54M | $2.87M | $195.00K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $-1.46M | $-1.92M | $-812.00K | $- |
| Long Term Investments | $- | $261.00K | $261.00K | $157.00K | $123.00K |
| Tax Assets | $- | $1.20M | $1.66M | $655.00K | $- |
| Other Non-Current Assets | $382.00K | $690.00K | $792.00K | $157.00K | $- |
| Total Non-Current Assets | $20.90M | $8.56M | $10.34M | $3.03M | $318.00K |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $1.34B | $1.16B | $527.67M | $347.62M | $393.02M |
| Account Payables | $6.78M | $2.38M | $1.94M | $865.00K | $547.00K |
| Short Term Debt | $2.84M | $2.28M | $2.17M | $844.00K | $58.00K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $41.61M | $- | $- | $- | $- |
| Other Current Liabilities | $16.89M | $29.29M | $16.10M | $5.14M | $2.35M |
| Total Current Liabilities | $68.13M | $33.95M | $20.21M | $6.85M | $2.96M |
| Long Term Debt | $13.85M | $3.05M | $5.33M | $1.84M | $150.00K |
| Deferred Revenue Non-Current | $- | $-1.20M | $-1.66M | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $1.20M | $1.66M | $655.00K | $- |
| Other Non-Current Liabilities | $- | $104.00K | $104.00K | $-655.00K | $- |
| Total Non-Current Liabilities | $13.85M | $3.15M | $5.43M | $1.84M | $150.00K |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $81.97M | $37.10M | $25.64M | $8.69M | $3.11M |
| Preferred Stock | $- | $- | $- | $- | $393.02M |
| Common Stock | $4.00K | $3.00K | $3.00K | $3.00K | $3.00K |
| Retained Earnings | $-997.89M | $-564.21M | $-287.87M | $-144.07M | $-75.51M |
| Accumulated Other Comprehensive Income Loss | $211.00K | $-3.29M | $-497.00K | $39.00K | $5.00K |
| Other Total Stockholders Equity | $2.25B | $1.69B | $790.39M | $482.95M | $72.40M |
| Total Stockholders Equity | $1.25B | $1.13B | $502.03M | $338.93M | $389.92M |
| Total Equity | $1.25B | $1.13B | $502.03M | $338.93M | $389.92M |
| Total Liabilities and Stockholders Equity | $1.34B | $1.16B | $527.67M | $347.62M | $393.02M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.34B | $1.16B | $527.67M | $347.62M | $393.02M |
| Total Investments | $1.08B | $875.72M | $287.04M | $269.28M | $180.47M |
| Total Debt | $16.69M | $5.33M | $7.50M | $2.69M | $208.00K |
| Net Debt | $-169.13M | $-243.00M | $-199.45M | $-50.36M | $-208.72M |
Balance Sheet Charts
| Breakdown | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $185.82M | $184.47M | $263.60M | $562.66M | $248.33M | $628.32M | $136.10M | $176.20M | $206.95M | $252.22M | $345.65M | $353.69M | $53.05M | $44.79M | $133.87M | $190.65M | $208.93M | $54.14M | $10.49M | $84.28M |
| Short Term Investments | $1.08B | $1.16B | $1.17B | $909.76M | $875.72M | $563.72M | $271.32M | $266.98M | $287.04M | $246.68M | $197.98M | $217.61M | $269.28M | $300.11M | $233.71M | $192.85M | $180.47M | $107.46M | $64.80M | $- |
| Cash and Short Term Investments | $1.26B | $1.34B | $1.43B | $1.47B | $1.12B | $1.19B | $407.41M | $443.19M | $493.99M | $498.90M | $543.63M | $571.29M | $322.33M | $344.90M | $367.58M | $383.49M | $389.40M | $161.60M | $75.30M | $84.28M |
| Net Receivables | $4.90M | $4.90M | $- | $- | $57.00K | $81.00K | $4.75M | $- | $1.75M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $32.83M | $7.50M | $- | $- | $28.32M | $24.88M | $10.72M | $- | $20.89M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $14.77M | $11.49M | $6.69M | $35.34M | $2.34M | $2.68M | $1.30M | $1.95M | $708.00K | $697.00K | $783.00K | $535.00K | $1.09M | $262.00K | $255.00K | $317.00K | $485.00K | $223.00K | $63.00K | $46.00K |
| Total Current Assets | $1.32B | $1.37B | $1.45B | $1.51B | $1.15B | $1.22B | $424.18M | $464.64M | $517.33M | $529.44M | $567.10M | $590.02M | $344.60M | $361.22M | $374.86M | $386.67M | $392.71M | $163.93M | $79.05M | $85.13M |
| Property Plant Equipment Net | $20.51M | $19.32M | $19.62M | $7.93M | $7.88M | $8.05M | $8.66M | $9.07M | $9.54M | $9.89M | $9.10M | $1.98M | $2.87M | $3.06M | $2.80M | $2.89M | $195.00K | $176.00K | $186.00K | $145.00K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $-1.46M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $-2.03M | $-2.03M | $- | $261.00K | $261.00K | $261.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $1.20M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $382.00K | $2.42M | $2.57M | $479.00K | $690.00K | $423.00K | $455.00K | $764.00K | $792.00K | $769.00K | $990.00K | $1.27M | $157.00K | $157.00K | $157.00K | $157.00K | $123.00K | $123.00K | $123.00K | $123.00K |
| Total Non-Current Assets | $20.90M | $19.70M | $20.16M | $8.41M | $8.56M | $8.73M | $9.38M | $9.84M | $10.34M | $10.66M | $10.09M | $3.25M | $3.03M | $3.22M | $2.96M | $3.05M | $318.00K | $299.00K | $309.00K | $268.00K |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $1.34B | $1.39B | $1.47B | $1.52B | $1.16B | $1.23B | $433.56M | $474.47M | $527.67M | $540.10M | $577.19M | $593.26M | $347.62M | $364.44M | $377.82M | $389.72M | $393.02M | $164.23M | $79.36M | $85.40M |
| Account Payables | $6.78M | $2.94M | $1.10M | $476.00K | $2.38M | $15.72M | $3.92M | $1.48M | $1.94M | $1.99M | $1.97M | $1.30M | $865.00K | $1.15M | $773.00K | $603.00K | $547.00K | $158.00K | $960.00K | $854.00K |
| Short Term Debt | $2.84M | $1.80M | $1.98M | $2.07M | $2.28M | $2.28M | $2.26M | $2.22M | $2.17M | $2.13M | $1.96M | $862.00K | $844.00K | $827.00K | $674.00K | $624.00K | $58.00K | $56.00K | $55.00K | $18.00K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $41.61M | $44.13M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $16.89M | $104.00K | $35.52M | $22.69M | $29.29M | $22.75M | $17.69M | $12.23M | $16.10M | $11.66M | $6.38M | $4.47M | $5.14M | $3.15M | $2.62M | $1.43M | $2.35M | $1.32M | $1.26M | $1.29M |
| Total Current Liabilities | $68.13M | $48.97M | $38.60M | $25.24M | $33.95M | $40.74M | $23.87M | $15.92M | $20.21M | $15.78M | $10.31M | $6.63M | $6.85M | $5.12M | $4.07M | $2.65M | $2.96M | $1.53M | $2.27M | $2.17M |
| Long Term Debt | $13.85M | $13.81M | $13.83M | $2.69M | $3.05M | $3.61M | $4.17M | $4.76M | $5.33M | $5.89M | $6.44M | $1.62M | $1.84M | $2.06M | $1.94M | $2.12M | $150.00K | $164.00K | $179.00K | $194.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $-1.20M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $1.20M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $104.00K | $104.00K | $104.00K | $104.00K | $104.00K | $104.00K | $104.00K | $104.00K | $104.00K | $104.00K | $- | $- | $- | $- | $- | $- | $123.89M | $121.81M |
| Total Non-Current Liabilities | $13.85M | $13.81M | $13.94M | $2.80M | $3.15M | $3.71M | $4.28M | $4.86M | $5.43M | $5.99M | $6.54M | $1.72M | $1.84M | $2.06M | $1.94M | $2.12M | $150.00K | $164.00K | $124.07M | $122.00M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $81.97M | $62.78M | $52.54M | $28.03M | $37.10M | $44.46M | $28.15M | $20.79M | $25.64M | $21.77M | $16.85M | $8.35M | $8.69M | $7.18M | $6.01M | $4.78M | $3.11M | $1.70M | $126.35M | $124.17M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $389.72M | $- | $164.23M | $1.00K | $- |
| Common Stock | $4.00K | $4.00K | $4.00K | $4.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $2.00K | $-1.00K | $- |
| Retained Earnings | $-997.89M | $-884.06M | $-764.94M | $-661.78M | $-564.21M | $-488.00M | $-411.03M | $-346.09M | $-287.87M | $-259.91M | $-208.98M | $-174.56M | $-144.07M | $-120.06M | $-101.22M | $-84.17M | $-75.51M | $-67.74M | $-58.70M | $-43.56M |
| Accumulated Other Comprehensive Income Loss | $211.00K | $-2.93M | $-3.64M | $-1.61M | $-3.29M | $-3.70M | $-3.00M | $-2.54M | $-497.00K | $-35.00K | $-5.00K | $9.00K | $39.00K | $370.00K | $897.00K | $1.57M | $5.00K | $50.00K | $71.00K | $- |
| Other Total Stockholders Equity | $2.25B | $2.21B | $2.19B | $2.15B | $1.69B | $1.68B | $819.43M | $802.31M | $790.39M | $778.27M | $769.32M | $759.47M | $482.95M | $476.94M | $472.12M | $77.82M | $465.42M | $65.99M | $11.64M | $4.79M |
| Total Stockholders Equity | $1.25B | $1.32B | $1.42B | $1.49B | $1.13B | $1.18B | $405.41M | $453.69M | $502.03M | $518.33M | $560.34M | $584.91M | $338.93M | $357.26M | $371.80M | $384.94M | $389.92M | $162.53M | $-46.99M | $-38.77M |
| Total Equity | $1.25B | $1.32B | $1.42B | $1.49B | $1.13B | $1.18B | $405.41M | $453.69M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $1.34B | $1.39B | $1.47B | $1.52B | $1.16B | $1.23B | $433.56M | $474.47M | $527.67M | $540.10M | $577.19M | $593.26M | $347.62M | $364.44M | $377.82M | $389.72M | $393.02M | $164.23M | $79.36M | $85.40M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.34B | $1.39B | $1.47B | $1.52B | $1.16B | $1.23B | $433.56M | $474.47M | $527.67M | $540.10M | $577.19M | $593.26M | $347.62M | $364.44M | $377.82M | $389.72M | $393.02M | $164.23M | $79.36M | $85.40M |
| Total Investments | $1.08B | $1.16B | $1.17B | $909.76M | $875.72M | $563.72M | $271.32M | $266.98M | $287.04M | $246.68M | $197.98M | $217.61M | $269.28M | $300.11M | $233.71M | $192.85M | $180.47M | $107.46M | $64.80M | $- |
| Total Debt | $16.69M | $15.61M | $15.81M | $4.76M | $5.33M | $5.89M | $6.44M | $6.98M | $7.50M | $8.02M | $8.40M | $2.48M | $2.69M | $2.88M | $2.62M | $2.75M | $208.00K | $220.00K | $234.00K | $212.00K |
| Net Debt | $-169.13M | $-168.86M | $-247.79M | $-557.90M | $-243.00M | $-622.43M | $-129.66M | $-169.22M | $-199.45M | $-244.20M | $-337.25M | $-351.20M | $-50.36M | $-41.90M | $-131.25M | $-187.90M | $-208.72M | $-53.92M | $-10.26M | $-84.06M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-433.68M | $-276.34M | $-143.81M | $-68.55M | $-43.96M |
| Depreciation and Amortization | $1.70M | $1.11M | $506.00K | $145.00K | $58.00K |
| Deferred Income Tax | $- | $- | $- | $- | $135.00K |
| Stock Based Compensation | $74.60M | $47.45M | $29.81M | $13.47M | $12.57M |
| Change in Working Capital | $9.53M | $4.77M | $10.85M | $-15.58M | $599.00K |
| Accounts Receivables | $57.00K | $1.69M | $-1.75M | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $4.35M | $243.00K | $1.07M | $318.00K | $278.00K |
| Other Working Capital | $5.12M | $2.84M | $11.52M | $-15.90M | $321.00K |
| Other Non Cash Items | $-37.97M | $-5.01M | $1.76M | $662.00K | $-326.00K |
| Net Cash Provided by Operating Activities | $-385.82M | $-228.01M | $-100.88M | $-69.86M | $-30.92M |
| Investments in Property Plant and Equipment | $-2.92M | $-915.00K | $-3.07M | $-419.00K | $-115.00K |
| Acquisitions Net | $3.92M | $1.22M | $3.15M | $419.00K | $115.00K |
| Purchases of Investments | $-1.52B | $-930.28M | $-400.83M | $-344.21M | $-231.72M |
| Sales Maturities of Investments | $1.36B | $344.80M | $381.21M | $254.98M | $57.50M |
| Other Investing Activities | $-3.92M | $-1.22M | $-3.15M | $-419.00K | $-115.00K |
| Net Cash Used for Investing Activities | $-160.32M | $-586.39M | $-22.69M | $-89.65M | $-174.34M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $487.90M | $- | $- | $3.66M | $330.08M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $483.37M | $855.78M | $277.57M | $3.66M | $405.28M |
| Net Cash Used Provided by Financing Activities | $483.37M | $855.78M | $277.57M | $3.66M | $405.28M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-62.77M | $41.38M | $154.01M | $-155.85M | $200.03M |
| Cash at End of Period | $185.82M | $248.59M | $207.21M | $53.20M | $209.05M |
| Cash at Beginning of Period | $248.59M | $207.21M | $53.20M | $209.05M | $9.03M |
| Operating Cash Flow | $-385.82M | $-228.01M | $-100.88M | $-69.86M | $-30.92M |
| Capital Expenditure | $-2.92M | $-915.00K | $-3.07M | $-419.00K | $-115.00K |
| Free Cash Flow | $-388.74M | $-228.92M | $-103.95M | $-70.28M | $-31.04M |
Cash Flow Charts
| Breakdown | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-113.82M | $-119.12M | $-103.16M | $-97.57M | $-76.21M | $-76.96M | $-64.94M | $-58.22M | $-27.96M | $-50.93M | $-34.42M | $-30.50M | $-24.01M | $-18.84M | $-17.05M | $-8.66M | $-7.77M | $-9.04M | $-15.14M | $-12.01M |
| Depreciation and Amortization | $447.00K | $458.00K | $469.00K | $327.00K | $305.00K | $290.00K | $269.00K | $248.00K | $236.00K | $106.00K | $52.00K | $112.00K | $48.00K | $43.00K | $33.00K | $21.00K | $21.00K | $15.00K | $12.00K | $10.00K |
| Deferred Income Tax | $112.51M | $- | $-112.51M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $135.00K |
| Stock Based Compensation | $22.79M | $18.30M | $18.00M | $15.51M | $12.66M | $12.02M | $12.13M | $10.64M | $8.32M | $8.20M | $7.47M | $5.82M | $4.47M | $4.14M | $3.23M | $1.63M | $981.00K | $1.64M | $6.84M | $3.10M |
| Change in Working Capital | $-10.08M | $1.28M | $29.91M | $-11.58M | $-10.83M | $5.50M | $12.86M | $-2.75M | $12.05M | $-1.50M | $-2.20M | $2.49M | $-4.42M | $-7.93M | $-2.36M | $-876.00K | $425.00K | $-530.00K | $-1.54M | $2.25M |
| Accounts Receivables | $- | $- | $- | $57.00K | $24.00K | $4.67M | $-4.75M | $1.75M | $-1.75M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $3.93M | $1.72M | $593.00K | $-1.90M | $-13.53M | $11.81M | $2.45M | $-481.00K | $66.00K | $-96.00K | $779.00K | $322.00K | $-260.00K | $412.00K | $142.00K | $24.00K | $389.00K | $-364.00K | $-332.00K | $585.00K |
| Other Working Capital | $-14.01M | $-444.00K | $29.32M | $1.85M | $2.68M | $-10.98M | $15.17M | $-4.02M | $13.74M | $-1.40M | $-2.98M | $2.16M | $-4.16M | $-8.34M | $-2.50M | $-900.00K | $36.00K | $-166.00K | $-1.21M | $1.66M |
| Other Non Cash Items | $-122.91M | $-10.91M | $103.16M | $-7.30M | $-4.68M | $-790.00K | $178.00K | $285.00K | $353.00K | $312.00K | $202.00K | $898.00K | $965.00K | $-199.00K | $358.00K | $-462.00K | $-473.00K | $-505.00K | $257.00K | $395.00K |
| Net Cash Provided by Operating Activities | $-111.06M | $-110.00M | $-64.13M | $-100.63M | $-78.76M | $-59.95M | $-39.50M | $-49.80M | $-7.00M | $-43.81M | $-28.89M | $-21.18M | $-22.95M | $-22.78M | $-15.79M | $-8.34M | $-6.82M | $-8.42M | $-9.57M | $-6.11M |
| Investments in Property Plant and Equipment | $-799.00K | $-629.00K | $-775.00K | $-714.00K | $-290.00K | $-174.00K | $-451.00K | $206.00K | $-769.00K | $-1.52M | $-739.00K | $-47.00K | $-82.00K | $-104.00K | $-157.00K | $-76.00K | $-40.00K | $-5.00K | $-53.00K | $-17.00K |
| Acquisitions Net | $-847.00K | $-28.94M | $252.81M | $847.00K | $1.22M | $291.85M | $- | $- | $3.15M | $- | $- | $66.00K | $419.00K | $- | $- | $197.00K | $-64.35M | $- | $- | $- |
| Purchases of Investments | $-226.19M | $-367.86M | $-605.80M | $-320.68M | $-470.93M | $-368.85M | $-42.20M | $-48.30M | $-111.33M | $-99.05M | $-109.59M | $-80.86M | $-80.24M | $-131.73M | $-61.90M | $-70.35M | $-100.08M | $-67.17M | $- | $- |
| Sales Maturities of Investments | $319.43M | $396.80M | $353.00M | $293.90M | $164.60M | $77.00M | $37.10M | $66.10M | $70.07M | $50.20M | $128.94M | $132.00M | $109.98M | $65.00M | $20.00M | $60.00M | $27.50M | $25.00M | $- | $5.00M |
| Other Investing Activities | $847.00K | $28.94M | $-252.81M | $-847.00K | $-1.22M | $-291.85M | $-5.10M | $-206.00K | $-3.15M | $- | $- | $-66.00K | $-419.00K | $- | $- | $-197.00K | $64.35M | $- | $-64.47M | $- |
| Net Cash Used for Investing Activities | $92.44M | $28.31M | $-253.58M | $-27.49M | $-306.62M | $-292.02M | $-5.55M | $17.80M | $-42.02M | $-50.37M | $18.60M | $51.10M | $29.66M | $-66.83M | $-42.05M | $-10.43M | $-72.62M | $-42.18M | $-64.52M | $4.98M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $24.39M | $2.66M | $18.40M | $442.45M | $- | $- | $- | $- | $- | $- | $- | $- | $4.10M | $- | $- | $- | $234.62M | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $19.87M | $2.66M | $18.40M | $442.45M | $5.38M | $844.19M | $4.95M | $1.26M | $3.75M | $749.00K | $2.25M | $270.82M | $1.54M | $525.00K | $1.07M | $517.00K | $234.22M | $94.24M | $314.00K | $76.50M |
| Net Cash Used Provided by Financing Activities | $19.87M | $2.66M | $18.40M | $442.45M | $5.38M | $844.19M | $4.95M | $1.26M | $3.75M | $749.00K | $2.25M | $270.82M | $1.54M | $525.00K | $1.07M | $517.00K | $234.22M | $94.24M | $314.00K | $76.50M |
| Effect of Forex Changes on Cash | $-196.16M | $- | $196.16M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $1.25M | $-79.03M | $-299.32M | $314.33M | $-379.99M | $492.22M | $-40.11M | $-30.75M | $-45.27M | $-93.43M | $-8.04M | $300.74M | $8.26M | $-89.09M | $-56.77M | $-18.25M | $154.78M | $43.65M | $-73.78M | $75.37M |
| Cash at End of Period | $185.82M | $184.57M | $263.60M | $562.92M | $248.59M | $628.58M | $136.36M | $176.46M | $207.21M | $252.48M | $345.91M | $353.95M | $53.20M | $44.94M | $134.03M | $190.80M | $209.05M | $54.27M | $10.62M | $84.40M |
| Cash at Beginning of Period | $184.57M | $263.60M | $562.92M | $248.59M | $628.58M | $136.36M | $176.46M | $207.21M | $252.48M | $345.91M | $353.95M | $53.20M | $44.94M | $134.03M | $190.80M | $209.05M | $54.27M | $10.62M | $84.40M | $9.03M |
| Operating Cash Flow | $-111.06M | $-110.00M | $-64.13M | $-100.63M | $-78.76M | $-59.95M | $-39.50M | $-49.80M | $-7.00M | $-43.81M | $-28.89M | $-21.18M | $-22.95M | $-22.78M | $-15.79M | $-8.34M | $-6.82M | $-8.42M | $-9.57M | $-6.11M |
| Capital Expenditure | $-799.00K | $-629.00K | $-775.00K | $-714.00K | $-290.00K | $-174.00K | $-451.00K | $206.00K | $-769.00K | $-1.52M | $-739.00K | $-47.00K | $-82.00K | $-104.00K | $-157.00K | $-76.00K | $-40.00K | $-5.00K | $-53.00K | $-17.00K |
| Free Cash Flow | $-111.86M | $-110.63M | $-64.91M | $-101.34M | $-79.05M | $-60.12M | $-39.95M | $-49.60M | $-7.77M | $-45.33M | $-29.63M | $-21.23M | $-23.03M | $-22.89M | $-15.95M | $-8.42M | $-6.86M | $-8.42M | $-9.63M | $-6.13M |
Karuna Therapeutics Dividends
Explore Karuna Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Karuna Therapeutics News
Read the latest news about Karuna Therapeutics, including recent articles, headlines, and updates.
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update. “2023 was a landmark year for Karuna, marked by the FDA acceptance of our NDA for KarXT for the treatment of schizophrenia in adults, with.
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna Therapeutics, Inc. (NasdaqGM: KRTX) to Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Karuna will receive $330.00 in cash for each share of Karuna that they own. KSF is seeking to determine whether this consideration and the process that led to it.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Karuna Therapeutics, Inc.
NEW YORK , Dec. 22, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Karuna Therapeutics, Inc. (NASDAQ: KRTX) and its board of directors concerning the proposed acquisition of the company by Bristol Myers Squibb (NYSE: BMY). Stockholders will receive $330.00 for each share of Karuna Therapeutics stock that they hold.
Bristol Myers Squibb buys neurological drug developer Karuna Therapeutics in $14B deal
Shares of biopharmaceutical company Karuna Therapeutics skyrocketed more than 47% Friday morning after giant Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) announced a deal to acquire the company in a $14 billion cash deal. The agreement valued Karuna at $330 per share.
Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook
U.S. equities headed into the long holiday weekend with gains at midday, amid a broad-based rally fueled by enthusiasm over the possibility of several Fed interest rate cuts next year. The Dow, S&P 500, and Nasdaq were all up.
Shareholder Alert: Ademi LLP investigates whether Karuna Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol-Myers
MILWAUKEE , Dec. 22, 2023 /PRNewswire/ -- Ademi LLP is investigating Karuna (NASDAQ: KRTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol-Myers. Click here to learn how to join the https://www.ademilaw.com/case/karuna-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.
KRTX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Karuna Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Karuna Therapeutics, Inc. (NASDAQ: KRTX) to Bristol Myers Squibb for $330.00 per share in cash is fair to Karuna shareholders. Halper Sadeh encourages Karuna shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Karu.
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
PRINCETON, N.J. & BOSTON--(BUSINESS WIRE)---- $KRTX--Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors. Ka.
Karuna Therapeutics' stock rockets into record territory after report Bristol Myers' $14 billion buyout agreement
Shares of Karuna Therapeutics Inc. KRTX, +1.80% rocketed 33.8% into record territory in premarket trading Friday, after The Wall Street Journal reported that Bristol Myers Squibb Co. BMY, +0.59% has reached an agreement to buy the drug developer in a deal valued at $14 billion. Bristol Myers' stock slumped 2.7% ahead of the open.
Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that results from the Phase 3 EMERGENT-2 trial of KarXT (xanomeline-trospium) in adults with schizophrenia were published in The Lancet. The manuscript shares KarXT data showcasing a clinically meaningful and statistically significant reduction in positive a.
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics, Inc. (Nasdaq: KRTX) ("Karuna") announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults. The application has been granted a Prescription Drug User Fee Act (PDUFA) date of Septembe.
Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults. The application has been granted a Prescription Drug User Fee Act (PDUFA) date of September.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for KRTX.